How does psilocybin affect the brain, particularly the default mode network?

Psilocybin appears to decrease activity within the default mode network (DMN). The DMN is associated with rumination and self-referential processing, which are often increased in depression. This reduction in DMN activity is compared to effects seen in long-term meditation.

Can psilocybin lead to long-term changes in personality?

Yes, studies suggest that psilocybin-induced mystical-type experiences can lead to enduring changes in personality, particularly an increase in openness. This is notable because personality traits are generally considered stable after early adulthood.

What are the risks associated with psilocybin use?

Risks include potential for difficult psychological experiences ('bad trips'), and in uncontrolled settings, people may put themselves or others at risk of physical harm. Vulnerable populations with pre-existing mental health conditions may be more susceptible to negative effects.

How does psilocybin compare to meditation for exploring consciousness?

Both psilocybin and meditation are seen as methods for investigating the nature of mind. Meditation is considered the 'tried-and-true' method for stabilizing awareness, while psilocybin might offer a 'crash course' due to abrupt shifts in consciousness, though it doesn't lead to the same stability.

What is the significance of mystical experiences in relation to psilocybin's effects?

Mystical-type experiences, characterized by unity, sacredness, and transcendence, are highly correlated with and possibly mediated by psilocybin's therapeutic effects. These profound experiences are often described as personally meaningful and having significant information value.

Are there any neurobiological mechanisms explained for psilocybin's effects?

Psilocybin binds to serotonin 2A receptors, and its major effects are thought to be downstream and likely glutamate-mediated. It also acutely decreases activity within the default mode network, a region associated with rumination.

What is the difference between psilocybin and Salvinorin A experiences?

While both are hallucinogens, Salvinorin A typically does not induce mystical experiences and is often not enjoyed, consistent with its action via dynorphin. Psilocybin, conversely, is associated with profound, meaningful, and often spiritually significant experiences.

What is the role of set and setting in psilocybin research?

The 'set' (mindset) and 'setting' (environment) are crucial and can significantly influence the psilocybin experience. Researchers carefully control these factors through preparation and support to maximize positive outcomes and minimize risks, though expectancy effects alone do not account for the full pharmacological impact.

Can psilocybin be used to treat addiction?

Yes, pilot studies show promising results for psilocybin in treating addictions, such as smoking cessation, with remarkably high abstinence rates. Research is ongoing for alcoholism and cocaine dependence.

What are the potential long-term effects on telomeres or gene expression?

Studies suggest meditation, and potentially the profound experiences related to psilocybin, may influence gene expression and telomere length, possibly due to stress reduction mechanisms, though direct psilocybin studies on this are not detailed here.

How are participants screened for psilocybin research?

Participants undergo extensive medical and history screening. A key exclusion criterion is having any second-degree relative with a history of psychotic or bipolar disorder, to mitigate risks associated with pre-existing vulnerabilities.

Roland Griffiths, Ph.D. on Psilocybin, Psychedelic Therapies & Mystical Experiences

FoundMyFitness

Education4 min read76 min video

Jan 19, 2017|132,949 views|3,199|243

Dr. Roland Griffiths Psilocybin Johns Hopkins Hallucinogens mystical experiences depression and anxiety meditation

Save to Pod

Key Moments

TL;DR

Psilocybin shows promise in treating depression, anxiety, and addiction, especially in cancer patients, by inducing profound experiences and neuroplasticity.

Key Insights

Psilocybin, a classic psychedelic, can induce deeply meaningful and spiritually significant experiences in carefully selected and supported individuals.

These psilocybin-induced experiences are often described as mystical, characterized by unity, interconnectedness, and a sense of truth, leading to long-lasting attitudinal and behavioral changes.

Research indicates psilocybin significantly reduces anxiety and depression in terminally ill cancer patients after a single dose, with effects lasting up to six months.

Psilocybin's therapeutic effects may be linked to its impact on the default mode network (DMN), decreasing activity associated with rumination and self-referential processing, similar to meditation.

Emerging research suggests psilocybin may promote neurogenesis and neuroplasticity, potentially allowing for the reorganization of brain connections and enduring changes in personality traits like openness.

Psilocybin shows remarkable potential in treating addiction, with a pilot study showing an 80% abstinence rate in smokers when combined with cognitive behavioral therapy.

While promising, psilocybin use carries risks, particularly for individuals with predispositions to psychotic disorders, and requires careful administration in supportive contexts to mitigate psychological distress and potential harm.

INTRODUCTION TO PSYCHEDELIC RESEARCH

Dr. Roland Griffiths, a clinical pharmacologist at Johns Hopkins, has dedicated over 40 years to researching mood-altering compounds. His interest in altered states of consciousness, sparked by meditation, led him to investigate classic psychedelics like psilocybin. This research aims to understand the profound and lasting effects these substances can have, particularly their potential for therapeutic applications and personal transformation, moving beyond their historical association with recreational use.

THE NATURE OF PSILOCYBIN EXPERIENCES

Psilocybin, when administered in controlled settings with careful participant selection and support, can induce experiences described as deeply meaningful and spiritually significant. These experiences often feature a sense of unity and interconnectedness, described as having profound truth value that participants reflect upon for months or even years. This contrasts with many other mood-altering substances, where the memory of the experience fades without lasting personal insight or change.

THERAPEUTIC APPLICATIONS IN CANCER PATIENTS

A significant area of research focuses on psilocybin's efficacy in alleviating anxiety and depression in patients with life-threatening cancer diagnoses. Traditional treatments often prove insufficient for the existential distress these patients face. Studies at Johns Hopkins and NYU have shown that a single psilocybin session can lead to substantial and sustained reductions in these symptoms, with benefits extending up to six months, offering considerable hope for improving quality of life in this population.

NEUROBIOLOGICAL MECHANISMS AND NEUROPLASTICITY

Research suggests psilocybin's effects are mediated through serotonin 2A receptors, potentially with downstream glutamate system involvement, similar to ketamine's antidepressant action. Neuroimaging studies indicate psilocybin acutely decreases activity in the default mode network (DMN), which is associated with rumination and self-referential thought, a state also observed in long-term meditators. This neurobiological impact, coupled with reports of increased personality openness and potential neurogenesis, points towards psilocybin's ability to foster profound neuroplastic changes.

POTENTIAL IN ADDICTION AND OTHER DISORDERS

The profound 'reorganizational experiences' induced by psilocybin show promise for treating addiction. A pilot study on smoking cessation, integrating psilocybin with cognitive behavioral therapy, achieved an an 80% abstinence rate at six months, far exceeding current treatment benchmarks. This suggests psilocybin-induced experiential shifts may extend to other conditions like alcoholism, cocaine dependence, PTSD, and OCD, highlighting its broad therapeutic potential when embedded within appropriate support structures.

RISKS, CONTROLS, AND FUTURE DIRECTIONS

Despite its potential, psilocybin use carries risks of challenging psychological experiences, particularly for individuals with pre-existing vulnerabilities. The research prioritizes rigorous screening and supportive 'set and setting'—the psychological and physical environment for the experience. While expectancy plays a role, psilocybin's effects are not solely placebo-driven. Future research aims for phase three clinical trials, with potential FDA approvability under strictly controlled conditions, emphasizing the critical interaction between pharmacology and therapeutic context.

COMPARISON WITH MEDITATION AND OTHER SUBSTANCES

Psilocybin's effect of decreasing DMN activity parallels the benefits seen in long-term meditation, offering a potential 'crash course' in altered awareness, though it lacks meditation's stabilizing effects. Unlike classic psychedelics, Salvinorin A (a kappa-opioid agonist) does not typically produce mystical experiences and is generally not considered enjoyable, despite affecting consciousness. DMT, while short-acting, shares serotonergic mechanisms with psilocybin, with Ayahuasca (DMT plus an MAO inhibitor) providing a more prolonged experience akin to psilocybin.

INDIGENOUS USE AND CULTURAL CONTEXT

The use of psilocybin, DMT, and mescaline (peyote) has deep roots in indigenous cultures across the Americas, often integrated into religious, healing, or divinatory practices. This historical use, typically within highly controlled cultural contexts, suggests an inherent value placed on the meaningfulness of emergent experiences. This contrasts with casual use and underscores the importance of context and intention when considering the therapeutic application of these powerful compounds.

Mentioned in This Episode

●Supplements

●Products

●Tools

●Organizations

●Concepts

●People Referenced

Common Questions

Psilocybin is discussed for its potential therapeutic benefits in treating anxiety and depression in late-stage cancer patients, as well as for treatment-resistant depression. It's also being explored for its efficacy in addiction treatments, such as smoking cessation.

Topics

Drug Research

Mentioned in this video

mediaTEDMED

A platform where Dr. Roland Griffiths has given a talk, mentioned as a way for people to find more information about him.

organizationNational Institute on Drug Abuse

The primary funder of Dr. Griffiths's early research on mood-altering compounds.

conceptkappa-opioid receptor

Receptor targeted by dynorphin and Salvinorin A, implicated in mood regulation and stress response.

toolmeditation

A practice discussed as a convergent methodology for investigating the mind, which shares similarities with psilocybin's effects on the default mode network and is considered a 'tried-and-true' path for awareness stability.

concept5-HT2A receptors

Serotonin receptors that psilocybin (and other classic hallucinogens) bind to, which are also targets for many antidepressants.

conceptneurogenesis

The process of generating new neurons, which studies suggest may be increased by psilocybin, potentially contributing to its therapeutic effects.

locationdentate gyrus

A region in the hippocampus, part of the brain, where psilocybin has been shown to increase neurogenesis in animal studies.

supplementdynorphin

An endogenous opioid that acts as a counter-balance to endorphins, potentially involved in thermoregulation and stress response.

drugSalvinorin A

A compound from the Salvia divinorum plant, acting on the kappa-opioid pathway, which produces dissociative effects but typically not mystical ones, and is short-acting.

conceptmu-opioid receptors

Receptors that bind to beta-endorphins, which may become sensitized through kappa-opioid receptor agonism.

conceptVipassana

A form of mindfulness meditation practiced by many long-term meditators studied.

supplementbeta-endorphins

Endogenous opioids that produce feelings of pleasure and pain relief, which mu-opioid receptors bind to.

drugMAO inhibitor

A type of drug that slows down the metabolism of DMT in the gut, extending its duration of action and making it comparable to psilocybin when consumed in Ayahuasca.

supplementAyahuasca

organizationTEDx

supplementDMT